RPG Life Sciences plans to invest ₹500 crore in manufacturing and API expansion, targeting significant growth by 2030.

RPG Active Pharma is acquiring Raghava Life Sciences' API and intermediates business. This strategic move aims to strengthen its integrated API play and manufacturing footprint.…

RPG Life Sciences is acquiring Raghava Life Sciences' API business for ₹135 crore, enhancing its manufacturing and product portfolio.